Comparison of Health State Utilities Using Community and Patient Preference Weights Derived from a Survey of Patients with HIV/AIDS

Objectives . The authors compare health state utilities derived from a national survey of patients with HIV/AIDS to represent community-based preferences with utilities derived from the same survey representing patient preferences; explore the relationships between these utilities and the dimensions of the SF-6D health state classification; and examine the implications of differences in the source of utilities for a cost-effectiveness analysis of early treatment of patients with HIV/AIDS. Methods . The authors derived community-based standard gamble (SG) utilities using an algorithm developed for the SF-6D health state classification system. The authors derived patient SG utilities from HIV/AIDS patient rating scale self-assessments using a power transformation. Data were from the HIV Cost and Services Utilization Study, a probability sample of 2864 HIV-infected adults receiving care in the United States in 1996. Results . Patient SG utilities were higher than community SG utilities by 4% to 9% (0.979 vs.0.937, 0.910 vs. 0.841, and 0.845 vs. 0.778; P < 0.001 for all comparisons). In regression analyses, patient SG utilities were less influenced by physical functioning, pain, and mental health dimensions of the SF-6D. The base case results of a cost-effectiveness analysis comparing early antiretroviral therapy to deferred therapy were unaffected by the choice between community ($20,100 per quality-adjusted life year) and patient ($18,400 per quality-adjusted life year) perspectives. The impact of the choice of utilities remained small in sensitivity analyses that varied the influence of treatment side effects on utilities and the initial symptom status of patients. Conclusion . There are differences between community and patient utilities for HIV/AIDS health states, although even when treatment side effects are important, these differences may not affect cost-effectiveness ratios.

[1]  P. Dolan Whose Preferences Count? , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  J. Brazier,et al.  Deriving a preference-based single index from the UK SF-36 Health Survey. , 1998, Journal of clinical epidemiology.

[3]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.

[4]  L. Kish,et al.  Inference from Complex Samples , 1974 .

[5]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[6]  D R Holtgrave,et al.  Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[7]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[8]  M. Weinstein,et al.  Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. , 2001, American journal of public health.

[9]  D A Revicki,et al.  Change in clinical status, health status, and health utility outcomes in HIV-infected patients. , 1995, Medical care.

[10]  N. Boyd,et al.  Whose Utilities for Decision Analysis? , 1990, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  C. Schur,et al.  National probability samples in studies of low-prevalence diseases. Part I: Perspectives and lessons from the HIV cost and services utilization study. , 1999, Health services research.

[12]  P. Royston Estimating departure from normality. , 1991, Statistics in medicine.

[13]  D. McCaffrey,et al.  National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV cost and services utilization study sample. , 1999, Health services research.

[14]  E. Adang,et al.  Response Shift and Adaptation in Chronically III Patients , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[15]  R Tibshirani,et al.  Describing Health States: Methodologic Issues in Obtaining Values for Health States , 1984, Medical care.

[16]  L A Lenert,et al.  Associations between health status and utilities implications for policy. , 1999, Medical care.

[17]  D. McCaffrey,et al.  The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. , 1998, The New England journal of medicine.

[18]  J E Ware,et al.  Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. , 1998, Journal of clinical epidemiology.

[19]  D. Feeny,et al.  Do They Have a Role in the Measurement of Preferences for Health States , 2001 .

[20]  P D Cleary,et al.  Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. , 2000, The American journal of medicine.

[21]  D. Podzamczer,et al.  A randomized study comparing instruments for measuring health-related quality of life in _HIV-infected patients , 1999 .

[22]  K. Tashima,et al.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.

[23]  D J Balaban,et al.  Weights for Scoring the Quality of Well-being Instrument Among Rheumatoid Arthritics: A Comparison to General Population Weights , 1986, Medical care.

[24]  M. Jones-Lee Personal willingness to pay for prevention: evaluating the consequences of accidents as a basis for preventive measures. , 1993, Addiction.

[25]  T. Merigan,et al.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .

[26]  J. Pater Quality of life and pharmacoeconomics in clinical trials , 1996 .

[27]  L. Lenert,et al.  The Effect of Search Procedures on Utility Elicitations , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  H. Doll,et al.  Evaluation of index and profile measures of health status in a randomized controlled trial. Comparison of the Medical Outcomes Study 36-Item Short Form Health Survey, EuroQol, and disease specific measures. , 1997, Medical care.

[29]  M C Weinstein,et al.  Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. , 1996, Medical care.

[30]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[31]  D. Zinner,et al.  Are Methods for Estimating QALYs in Cost-Effectiveness Analyses Improving? , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[32]  G. Torrance,et al.  The utility of different health states as perceived by the general public. , 1978, Journal of chronic diseases.

[33]  D. Feeny,et al.  Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. , 1996, Medical care.

[34]  P J Neumann,et al.  An Off-the-Shelf Help List , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[35]  M. Mcgrath Cost Effectiveness in Health and Medicine. , 1998 .

[36]  M C Weinstein,et al.  The cost-effectiveness of preventing AIDS-related opportunistic infections. , 1998, JAMA.

[37]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[38]  A. Wu,et al.  Health Values of the Seriously Ill , 1996, Annals of Internal Medicine.